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Impact of nocturnal hemodialysis on the variability of heart rate
and duration of hypoxemia during sleep.
Background. Nocturnal hemodialysis (NHD) alleviates
uremia-related sleep apnea, a condition characterized by in-
creased sympathetic activity and diminished heart rate (HR)
variability. We tested the hypothesis that NHD reduces
both hypoxemia and sympathetic neural contributions to HR
variability during sleep.
Methods. Episodes of apnea and hypopnea and the dura-
tion of nocturnal hypoxemia during sleep were determined in 9
end-stage renal disease (ESRD) patients (age: 44 ± 2) (mean ±
SEM) before and after conversion from conventional hemodial-
ysis (CHD) to NHD, and in 10 control subjects (age: 45 ± 3) with
normal renal function and without sleep apnea. Low frequency
(LF) (0.05-0.15 Hz) and high frequency (HF) (0.15-0.5 Hz) HR
spectral power during stage 2 sleep was calculated (Fast Fourier
transformation). Patients were studied 4 times (1 day before
and on the night after their CHD session) and 6–15 months
after conversion to NHD, while receiving NHD and on a non-
dialysis night.
Results. NHD decreased the frequency of apnea and hypop-
nea (from 29.7 ± 9.3 to 8.2 ± 2.0 episodes per hour, P = 0.02),
and duration of nocturnal hypoxemia (from 13.9 ± 5.2 to 2.6 ±
1.9% of total sleep time, P = 0.02). As CHD recipients, ESRD
patients had faster nocturnal heart rates (79 ± 2 vs. 58 ± 1 min−1,
P = 0.03) and lower HF (vagal) (78 ± 27 vs. 6726 ± 4556 ms2,
P = 0.001) spectral power than control subjects. After conver-
sion to NHD, HR fell (from 79 ± 2 to 66 ± 1 min−1, P = 0.03)
and HF power increased (from 78 ± 27 to 637 ± 139 ms2, P =
0.001). The HF/HF+LF ratio, an index of vagal HR modulation,
was lower during CHD (0.16 ± 0.03 vs. 0.42 ± 0.05 in control
subjects, P < 0.05) and increased (to 0.45 ± 0.05, P < 0.001)
after conversion to NHD. The LF/HF ratio, a representation
of sympathetic HR modulation, which was significantly higher
during CHD than in control subjects (2.77 ± 0.82 vs. 0.71 ± 0.11,
P < 0.05), was also normalized by NHD (0.74 ± 0.12, P < 0.05,
compared with CHD).
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Conclusion. Higher heart rates and impaired vagal and aug-
mented sympathetic HR modulation during sleep in ESRD pa-
tients are normalized by NHD. Potential mechanisms for these
observations include attenuation of surges in sympathetic out-
flow elicited by apnea and hypoxia during sleep, normalization
of nocturnal breathing patterns that influence HRV, and re-
moval, by increased dialysis, of a sympatho-excitatory stimulus
of renal origin.
Cardiovascular disease is the leading cause of death in
patients receiving conventional hemodialysis (CHD) for
end-stage renal disease (ESRD)[1]. Nocturnal hemodial-
ysis (NHD), which provides more intense and frequent
renal replacement therapy than CHD, beneficially mod-
ifies several key risk factors for morbid cardiovascular
events [2], such as hypertension [3], left ventricular hyper-
trophy [3] (LVH), and impaired left ventricular systolic
function [4].
The mechanisms by which NHD modifies these cardio-
vascular risk factors are under active investigation. Be-
cause NHD is administered overnight, it is possible that
more aggressive correction of uremia improves one or
more circulatory or autonomic disturbances specific to
sleep. Sleep-related breathing disorders, which are com-
mon in ESRD [5], are characterized by repetitive low and
very low frequency cycles of apnea, hypoxia, hypercap-
nia, and arousal [6]. Subjects with upper airway obstruc-
tion endure, in addition, sudden and profound changes in
cardiac loading conditions, secondary to the abrupt gen-
eration of negative intrathoracic pressure. Acutely, each
of these five stimuli acts independently to trigger salvos
of central sympathetic outflow to the heart and periph-
ery [7]. Increased cardiac and peripheral adrenergic drive
may help explain why sleep apnea and nocturnal hypox-
emia have been associated with LVH and hypertension
in the CHD population [8, 9].
Subjects with sleep apnea also exhibit marked re-
ductions in heart rate variability (HRV) while awake
[10]. Decreased variability of heart rate in general, and
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impaired vagal modulation of sino-atrial discharge in par-
ticular, are two potent markers of adverse cardiac events
and premature death following myocardial infarction [11]
and in patients with congestive heart failure [12, 13].
In heart failure, cardiac sympathetic activity is a potent
marker of premature cardiac death [14]. ESRD patients
also exhibit low vagal and high sympathetic neural mod-
ulation of heart rate [15].
NHD ameliorates uremia-related sleep apnea [16]. The
impact of this finding on the neural regulation of the heart
during sleep has yet to be defined. In the present study,
we applied power spectral analysis of HRV to test the hy-
pothesis that NHD would lower sympathetic modulation
of heart rate during sleep, and that this reduction would
relate to correction of nocturnal hypoxemia.
METHODS
Sleep studies were conducted at St. Michael’s Hospital.
Subjects were attended by a registered ploysomnographic
technologist. Study subjects were recruited from the pool
of Toronto based patients on CHD receiving training
in preparation for conversion to NHD. Part of their
polysomnographic data has been published previously
[16]. No subject had an acute illness. This experimental
protocol was approved by the Research Ethics Boards of
the St. Michael’s Hospital. Written informed consent was
obtained from each patient.
Protocol
Sleep studies from nine ESRD patients and 10 unmed-
icated control subjects matched for age, gender, and body
mass index with normal renal function, but without sleep
apnea, were analyzed. Each ESRD subject was studied
four times: twice while receiving CHD (1 day prior to
and then the night after their CHD session), and again 6
to 15 months after conversion to a stable dose of NHD.
The NHD studies were performed twice, on a night with-
out, and with dialysis administered concurrently. After
conversion, vasoactive medications could be withdrawn
by the patient’s own nephrologist in response to symp-
tomatic hypotension. All patients abstained from alcohol
and cigarette consumption during the study. Each control
subject was studied once.
Study measurements
During overnight polysomnography, we obtained
a two-channel electroencephalogram, an electro-
oculogram, and a submental electromyogram. Arterial
oxygen saturation was measured with a pulse oximeter
(Biox 3740; Ohmeda, Boulder, CO, USA). Airflow was
measured by the amount of expired carbon dioxide using
the CD 102 carbon dioxide analyzer (Normocap; Datex,
Helsinki, Finland). Respiratory effort was measured by
inductance plethysmography (Respitrace; Ambulatory
Monitoring, Ardsley, NY, USA). The electrocardiogram
was obtained with standard surface electrodes. All
variables were recorded continuously by a computerized
data acquisition system and recorded on optical disks for
later analysis (Sandman; Mallinckrodt/Nellcor-Puritan
Bennet, Melville, Ottawa, Canada).
All polysomnograms were scored manually according
to established criteria [17]. Apnea was defined as the ab-
sence of airflow for more than 10 seconds. Hypopnea
was defined as a reduction for more than 10 seconds in
the amplitude of respiratory effort to a value between
10% and 50% of the baseline level during sleep, with
or without an associated decrease in oxygen saturation.
The apnea-hypopnea index (AHI) was defined as the
number of episodes of apnea and hypopnea per hour of
sleep. The extent of nocturnal hypoxemia was determined
by the percent of total sleep time (%TST) with oxygen
saturation (SaO2) less than 90%.
Dialysis prescriptions
CHD entailed 4 hours of hemodialysis 3 times per
week. Vascular access was achieved through either a long-
term internal jugular catheter or an arteriovenous fis-
tula. A dialysate flow rate of 500 to 750 mL per minute
and F80 polysufone dialyzers (Fresenius Medical Care,
Lexington, MA, USA) were used. Once converted, pa-
tients received hemodialysis at home for 8 to 10 hours
6 nights per week using the same vascular access, a
dialysate flow rate of 100 mL per minute, and F40 poly-
sufone dialyzers (Fresenius Medical Care).
Short-term HRV
For each study, 7 minutes of continuous heart rate
recordings during stage 2 non-rapid eye movement
(NREM) sleep were acquired digitally and transferred
to a Labview (National Instruments, Austin, TX, USA)
based software system for Fast Fourier transformation as
previously reported [18]. Low-frequency (LF) harmonic
(0.05–0.15 Hz) and high-frequency (HF) harmonic (0.15–
0.5 Hz) contributions to spectral power were determined.
LF/LF+HF, HF/HF+LF, and LF/HF were used to esti-
mate sympathetic and vagal modulation of heart rate and
their ratio, respectively [19].
Biochemical analysis
Venous blood was withdrawn at the end of each
polysomnography session to determine blood urea nitro-
gen concentrations as a marker for uremia control.
Statistical analysis
Data are presented as mean ± standard error. Stu-
dent paired t test was applied to analyze within group
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Table 1. Patient demographics
Variables Patients (N = 9) Control (N = 10)
Age years 44 ± 2 45 ± 3
Gender M:F 5:4 6:4
Body mass index kg/m2 25 ± 2 24 ± 1
Etiology of ESRD Not applicable





Vasoactive medications 1.7 0.3a None








Abbreviations are: DM, diabetes mellitus; GN, glomerular disease; PCKD,
adult polycystic kidney disease; CHD, conventional hemodialysis; NHD,
nocturnal hemodialysis; ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin II receptor blocker; BB, beta receptor blocker; DCCB,
dihydropyridine calcium channel blocker; NDCCB, non-dihydropyridine class
of calcium channel blocker; a-blocker, alpha receptor blocker.
aDenotes P < 0.05.
comparisons, and unpaired t test was used for between
group comparisons for normally distributed variables.
The Mann-Whitney U rank sum test was used for abnor-
mally distributed variables. A two-tailed P value < 0.05
was employed to determine significance. This sample size
was determined to provide 80% to 90% power to detect
an alpha difference of 0.05.
RESULTS
The characteristics of these study subjects appear in
Table 1. There were no significant differences between
the two groups with respect to mean age, gender body
mass index, and total sleep time (TST) (Table 1). After
conversion from CHD to NHD, blood urea nitrogen fell
and there was a significant decrease in the need for an-
tihypertensive medications (Tables 1 and 2). One of the
ESRD patients required a benzodiazepine for sleep on
all four study nights.
AHI, nocturnal hypoxemia, and RR interval were sig-
nificantly higher in ESRD patients when receiving CHD
than in healthy control subjects. There was no difference
in quantitative measures of sleep apnea or of nocturnal
hypoxemia during the two CHD study sessions. After
conversion to NHD, there was a decrease in the frequency
of apnea and hypopnea, a reduction in the extent of hy-
poxemia, and a fall in heart rate during sleep during the
two NHD study sessions (Table 2).
Total heart rate spectral power and its different fre-
quency bands during sleep were lower in ESRD patients
when receiving CHD than in control subjects (Table 2).
The mean values of the HRV spectral data for the two
CHD and NHD sessions are reported below. Of the dif-
ferent frequency bands, HF spectral power was signifi-
cantly reduced in CHD patients as compared to control
subjects (78 ± 27 vs. 6726 ± 4556 ms2, P = 0.001) and in-
creased after conversion to NHD (to 637 ± 139 ms2, P <
0.001). HF/HF+LF, an index of vagal heart rate modula-
tion that was also diminished during CHD (0.16 ± 0.03
vs. 0.42 ± 0.05 in control subjects, P < 0.05) increased
significantly after conversion to NHD (to 0.45 ± 0.05 P <
0.001). The LF/HF ratio, which was significantly higher in
ESRD patients receiving CHD than in control subjects
(2.77 ± 0.82 vs. 0.71 ± 0.11, P < 0.05), returned to control
values (0.74 ± 0.12, P < 0.05 compared with CHD) after
conversion to NHD (Table 2).
DISCUSSION
In the ESRD population nocturnal hypoxemia [9] and
attenuated HRV [20] are two important risk factors for
subsequent cardiovascular events. In addition to noctur-
nal hypoxemia, our ESRD patients receiving CHD exhib-
ited reduced parasympathetic modulation, quicker heart
rates, and increased sympathetic modulation of HRV dur-
ing sleep. Augmentation of dialysis frequency and dose
by NHD reduced nocturnal apnea and hypopnea, low-
ered heart rate, and returned the autonomic modulation
of HRV during sleep to a relatively normal state of vagal-
sympathetic balance.
Normal non-rapid eye movement sleep is character-
ized by reductions in metabolic rate, sympathetic nervous
system activity, heart rate, cardiac output, and total pe-
ripheral resistance [7, 21]. Vagal tone increases [7, 22].
This normal autonomic balance is disturbed in patients
with ESRD. Vagal modulation of heart rate is attenuated,
and sympathetic modulation predominates [15, 23].
Giordano et al [24] examined 11 hemodialysis patients
and compared them to 10 normal control subjects. Ure-
mic patients had less HF power and greater LF power,
resulting in an increased LF/HF ratio. In addition, there
was a significant correlation between changes in HRV and
changes in plasma urea concentration after a single ses-
sion of CHD. These investigators proposed that uremia
elicits an increase in cardiac sympathetic activity that is
lessened, but not abolished, by conventional dialysis ther-
apy. Although this concept might seem paradoxical, in
that reductions in intravascular volume and blood pres-
sure with dialysis should increase efferent sympathetic
activity reflexively, by unloading cardiopulmonary and
arterial mechanoreceptor [25, 26], several investigators
have hypothesized that uremia can increase central sym-
pathetic outflow by stimulating an excitatory reflex aris-
ing from renal afferent nerves [27, 28]. If this hypothesis
is correct, then reducing uremia further by augment-
ing dialysis dose and frequency should attenuate effer-
ent sympathetic discharge to the heart and periphery.
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Table 2. Polysomnographic variables and heart rate variability in ESRD and control subjects
ESRD patients (N = 9) Normal Subjects (N = 10)
Variable CHD1 CHD2 CHD NHD1 NHD2 NHD Control
Total sleep time hours 5.4 ± 0.2 5.5 ± 0.2 5.5 ± 0.2 5.3 ± 0.2 5.2 ± 0.3 5.3 ± 0.3 5.8 ± 0.2
AHI episodes per hour 29.2 ± 9.9c 30.2 ± 9.8c 29.7 ± 9.3c 7.2 ± 3.3a,b 9.7 ± 2.9a,b 8.2 ± 2.0e 4.6 ± 1.8
%TST with O2 saturation < 90% 15.4 ± 7.2c 12.5 ± 7.5c 13.9 ± 5.2c 3.5 ± 3.4a,b 1.0 ± 0.5a,b 2.6 ± 1.9e 0.2 ± 0.2
Body mass index kg/m2 26.1 ± 1.9 25.5 ± 1.8 25.8 ± 1.5 26.1 ± 1.6 25.8 ± 1.7 25.9 ± 1.5 24.1 ± 1.0
Blood urea nitrogen mmol/L 24.6 ± 1.6 12.9 ± 0.9 18.8 ± 1.0 10.9 ± 0.8a,b 6.6 ± 0.5a,b 8.8 ± 0.6e N/A
RR intervals ms 829 ± 35c 795 ± 29c 763 ± 34c 912 ± 48a,b 913 ± 65a,b 913 ± 37e 978 ± 35
Total spectral power ms2 522 ± 177d 638 ± 328d 572 ± 166d 2402 ± 981 1544 ± 888 2061 ± 542 145893 ± 127529
LF ms2 202 ± 94d 85 ± 36d 152 ± 56d 356 ± 151 317 ± 196 340 ± 94 4788 ± 2648
HF ms2 100 ± 44d 48 ± 15d 78 ± 26d 712 ± 256a,b 533 ± 221a,b 637 ± 139e 6726 ± 4555
LF/LF+HF 0.60 ± 0.08 0.59 ± 0.10 0.59 ± 0.06 0.39 ± 0.06 0.39 ± 0.07 0.39 ± 0.05 0.42 ± 0.04
HF/LF+HF 0.14 ± 0.02c 0.17 ± 0.05c 0.16 ± 0.03c 0.32 ± 0.07a,b 0.61 ± 0.07a,b 0.45 ± 0.05e 0.42 ± 0.05
LF/HF 2.17 ± 0.54c 3.57 ± 1.81c 2.77 ± 0.82c 0.75 ± 0.22a 0.70 ± 0.18a 0.74 ± 0.12e 0.71 ± 0.11
Abbreviations are: AHI, apnea-hypopnea index; CHD1, Study conducted 1 day prior to routine conventional hemodialysis session; CHD2, Study conducted on the
night after routine conventional hemodialysis session; CHD, mean of CHD1 and CHD2; ESRD, end-stage renal disease; N/A, not applicable; NHD1, Study conducted
on a night without dialysis after conversion from conventional hemodialysis to nocturnal hemodialysis; NHD2, Study conducted on a night with dialysis after conversion
from conventional hemodialysis to nocturnal hemodialysis; NHD, mean of NHD1 and NHD2; %TST, Percent of total sleep time. There are no statistical significant
differences in polysomnographic and heart rate variability variables between CHD1, CHD2, and NHD1, NHD2.
aDenotes P < 0.05 compared with CHD1 using Student t test.
bDenotes P < 0.05 compared with CHD2 using Student t test.
cDenotes P < 0.05 compared with normal subjects using Student t test.
dDenotes P < 0.05 compared with normal subjects using Mann-Whitney rank-sum test.
eDenotes P < 0.05 compared with CHD using Student t test.
Consistent with this concept, we have since reported
for the first time a reduction in daytime plasma nore-
pinephrine concentrations one month after conversion
from CHD to NHD [abstract; Chan et al, Circulation
106(Suppl 2):486]. Our present findings demonstrate that
NHD also lowers heart rate during sleep and normalizes
its autonomic modulation.
Low-frequency oscillations in breathing patterns can
drive both heart rate and blood pressure to oscillate at
similar frequencies [18]. NHD should attenuate noctur-
nal low and very low frequency breathing patterns and
restore normal HF respiratory oscillations. Normaliza-
tion of nocturnal breathing patterns is therefore a sec-
ond mechanism by which this mode of dialysis could
reduce the LF/HF power spectral ratio during sleep. Noc-
turnal hypoxemia evokes adrenergic overactivity and va-
gal withdrawal in subjects with normal renal function
[29], and has similar actions in ESRD patients [30]. For
example, Zoccali et al, who studied 25 ESRD patients,
demonstrated that the degree of nocturnal hypoxemia
correlated with parasympathetic withdrawal, as assessed
by HRV and the presence of concentric LVH [31]. In
the non-ESRD population, abolition of obstructive ap-
nea and hypoxemia during sleep by nasal continuous pos-
itive airway pressure (CPAP) has been shown to signifi-
cantly lower daytime systolic blood pressure, heart rate,
and augment left ventricular systolic performance [32,
33].
Our present results add to the body of evidence that
uremia-related sleep apnea with oxygen desaturation is a
potent yet reversible stimulus to cardiac adrenergic drive.
Over time, restoration of normal autonomic regulation of
the circulation and reductions in blood pressure and to-
tal peripheral resistance with improved uremic clearance
and nocturnal normoxia could contribute importantly to
the regression of LVH and recovery of depressed left ven-
tricular systolic function shown to occur with long-term
(>2 years) NHD [3, 4].
CONCLUSION
ESRD patients undergoing CHD have high cardio-
vascular mortality. Nocturnal hypoxemia and impaired
autonomic modulation of HRV appear to contribute in-
dependently to their increase in risk for cardiovascular
events. In population studies, heart rate itself has been
shown to correlate inversely to longevity [34]. By aug-
menting dialysis dose and frequency with NHD, we cor-
rected night-time hypoxemia, lowered heart rate, and
returned the autonomic modulation of HRV during sleep
to a more normal state of vagal-sympathetic balance. In-
deed, because the majority of the antihypertensive ther-
apies with an autonomic neural action prescribed during
CHD improve HRV by enhancing its vagal and decreas-
ing its sympathetic modulations [35–37], their withdrawal
after conversion to NHD may have caused us to under-
estimate the true impact of NHD on heart rate and on its
autonomic modulation. Further prospective randomized
studies are required to characterize more precisely the
impact of NHD on sleep related breathing disorders and
on impaired sympathetic and parasympathetic modula-
tion of heart rate and on survival of ESRD patients.
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